TOI Quote, Financials, Valuation and Earnings

Pediatrix Medical Group, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of 14.55%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 82.58%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 5.97%. Given that The Oncology Institute, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Pediatrix Medical Group, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.542%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. The Oncology Institute, Inc.'s net income of -$13.8M is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.66x versus 0.95x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of -22162.75%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Kindly MD, Inc.'s return on equity of -91.57%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 82.58%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 256.02%. Given that Kindly MD, Inc. has higher upside potential than The Oncology Institute, Inc., analysts believe Kindly MD, Inc. is more attractive than The Oncology Institute, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. The Oncology Institute, Inc.'s net income of -$13.8M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.66x versus 9.84x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of -13.47%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat SRx Health Solutions, Inc.'s return on equity of --.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 82.58%. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that The Oncology Institute, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe The Oncology Institute, Inc. is more attractive than SRx Health Solutions, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.819%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. The Oncology Institute, Inc.'s net income of -$13.8M is lower than SRx Health Solutions, Inc.'s net income of -$964K. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.66x versus 0.04x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of 9.98%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat U.S. Physical Therapy, Inc.'s return on equity of 8.6%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 82.58%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 34.89%. Given that The Oncology Institute, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe The Oncology Institute, Inc. is more attractive than U.S. Physical Therapy, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.290, suggesting its more volatile than the S&P 500 by 28.981%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.31% to investors and pays a quarterly dividend of $0.45 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 95.62% of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are smaller than U.S. Physical Therapy, Inc. quarterly revenues of $197.1M. The Oncology Institute, Inc.'s net income of -$13.8M is lower than U.S. Physical Therapy, Inc.'s net income of $19.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while U.S. Physical Therapy, Inc.'s PE ratio is 32.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.66x versus 1.56x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.